2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Oral Oncology 79 (2018) 9–14

C.L. Barney et al.

of cetuximab in this population as an e ff ort to reduce morbidity should be approached with caution, especially in IR-RPA patients or in those with advanced nodal disease. When cetuximab is used in cisplatin in- eligible patients, AFRT should be considered in an e ff ort to improve LRC.

[10] Buglione M, Maddalo M, Corvò R, Pirtoli L, Paiar F, Lastrucci L, et al. Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck cancer. Int J Radiat Oncol • Biol • Phys 2017;97:462 – 72. http://dx.doi.org/10.1016/j.ijrobp.2016.10.011 . [11] Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyper- fractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: fi rst report of RTOG 9003. Int J Radiat Oncol 2000;48:7 – 16. http://dx.doi.org/10.1016/S0360- 3016(00)00663-5 . [12] Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous- cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003;362:933 – 40. http://dx.doi.org/10.1016/S0140-6736(03)14361-9 . [13] Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a rando- mised, controlled, open-label phase 2 trial. Lancet Oncol 2015;16:221 – 32. http:// dx.doi.org/10.1016/S1470-2045(14)71200-8 . [14] Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. E ff ect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitu- mumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol 2017;3:220 – 6. http://dx.doi.org/10.1001/ jamaoncol.2016.4510 . [15] Leibel SA, Scott CB, Mohiuddin M, Marcial VA, Coia LR, Davis LW, et al. The e ff ect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol 1991;21:549 – 56. http://dx.doi.org/10.1016/0360-3016(91)90669-U . [16] Garavello W, Ciardo A, Sprea fi co R, Gaini RM. Risk factors for distant metastases in [17] Oksuz DC, Prestwich RJ, Carey B, Wilson S, Senocak MS, Choudhury A, et al. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. Radiat Oncol 2011;6:54. http://dx.doi. org/10.1186/1748-717X-6-54 . [18] Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091 – 8 . [19] Oshita F, Kurata T, Kasai T, Fakuda M, Yamamoto N, Ohe Y, et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res Gann 1995;86:1198 – 202 . [20] Perez CA, Wu X, Amsbaugh MJ, Gosain R, Claudino WM, Yusuf M, et al. High-dose versus weekly cisplatin de fi nitive chemoradiotherapy for HPV-related orophar- yngeal squamous cell carcinoma of the head and neck. Oral Oncol 2017;67:24 – 8. http://dx.doi.org/10.1016/j.oraloncology.2017.01.010 . [21] Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, et al. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squamous cell carcinoma of the oropharynx (SCCOP). Head Neck 2014;36:617 – 23. http://dx.doi.org/10.1002/hed.23339 . [22] Gupta PK, Lal P, Bajpai R, Goel A, Yadav R, Verma M, et al. Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cis- platin with six fractions per week radiotherapy in locally advanced head neck cancer. South Asian J Cancer 2016;5:80 – 4. http://dx.doi.org/10.4103/2278-330X. 181647 . [23] Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. Once- a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol 2017. [JCO – 2017] . [24] Wilmington D, Konrad-Martin D, Helt W, Dille M, Gordon J, Fausti S. Ototoxicity monitoring: program approaches and considerations. Semin Hear 2011;32:248 – 61. http://dx.doi.org/10.1055/s-0031-1286619 . [25] Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol 2012;23:510 – 21. http://dx.doi.org/10.3766/jaaa.23.7.3 . head and neck squamous cell carcinoma. Arch Otolaryngol Neck Surg 2006;132:762 – 6. http://dx.doi.org/10.1001/archotol.132.7.762 .

Con fl ict of interest statement

None declared.

Acknowledgements

This research did not receive any speci fi c grant from funding agencies in the public, commercial, or not-for-pro fi t sectors.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.oraloncology.2018.02. 001 .

References

[1] Pignon J-P, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4 – 14. http://dx.doi.org/10.1016/j.radonc.2009. 04.014 . [2] Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta- analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33 – 40. http://dx.doi.org/10. 1016/j.radonc.2011.05.036 . [3] Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24 – 35. http://dx.doi.org/10.1056/NEJMoa0912217 . [4] Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567 – 78. http://dx.doi.org/10.1056/NEJMoa053422 . [5] Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registra- tion trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetux- imab. J Clin Oncol 2016;34:1300 – 8. http://dx.doi.org/10.1200/JCO.2015.62. 5970 . [6] Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21 – 8. http://dx.doi.org/10.1016/S1470- 2045(09)70311-0 . [7] Baxi SS, O ’ Neill C, Sherman EJ, Atoria CL, Lee NY, P fi ster DG, et al. Trends in chemoradiation use in elderly patients with head and neck cancer: changing treatment patterns with cetuximab. Head Neck 2016;38:E165 – 71. http://dx.doi. org/10.1002/hed.23961 . [8] Overgaard J, Mohanti BK, Begum N, Ali R, Agarwal JP, Kuddu M, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and

neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 2010;11:553 – 60. http://dx.doi.org/10.1016/S1470-2045(10)70072-3 .

[9] Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2016;39:27 – 31. http://dx.doi.org/10.1097/ COC.0000000000000006 .

98